Smoke Signals: What a Risk-Off London Means for Cannabis Shares

Highlights

• London's main indices are stuck near their weakest levels in weeks as Middle East tension and a fragile ceasefire keep traders cautious.

• Risk-off conditions tend to weigh hardest on speculative small caps, the segment where most UK cannabis names sit.

• Companies such as Celadon Pharmaceuticals and Kanabo Group remain focused on regulatory and commercial milestones rather than market noise.

London's equity market is having an uneasy week. The FTSE 100 and FTSE 250 are loitering near their lowest levels in weeks, weighed down by tension in the Middle East, a ceasefire that feels anything but secure, and a looming US inflation reading that has traders reluctant to commit. Oil has pushed higher on the geopolitical strain, gold has pulled back sharply after setting record highs earlier in the year, and the overall mood is unmistakably risk-off. In an environment like this, attention naturally gravitates to the blue chips and the big fallers of the day. But spare a thought for the market's smallest and most speculative corner: the cluster of cannabis and cannabinoid companies listed in London.

These businesses rarely make the front page on a day dominated by index-level anxiety. Yet the conditions gripping the wider market matter enormously to them, because sentiment is the oxygen on which early-stage, pre-profit companies survive. When investors retreat to consumer staples and defensive income payers, the flow of speculative capital that sustains small-cap healthcare and life sciences stories tends to dry up first.

Why does a risk-off market hit cannabis stocks hardest?

The answer comes down to the structure of the sector. The UK's listed cannabis companies are, almost without exception, small businesses at an early stage of commercialisation. Many are still working through clinical programmes, licensing processes or early revenue ramps. That means they periodically return to the market for funding, and their valuations rest heavily on what investors believe future cash flows might look like, rather than on profits being generated today.

When the broader market turns defensive, as it has this week, the discount investors apply to those distant cash flows widens. Liquidity in small caps thins out, spreads stretch, and even modest selling can move prices disproportionately. None of this reflects anything the companies themselves have done; it is simply the gravity of market mood. The same dynamic that punished growth stocks across the board in previous risk-off episodes applies with extra force to a sector that still carries regulatory and reputational baggage.

Who are the names to watch in London's cannabis cluster?

Celadon Pharmaceuticals (AIM:CEL) remains the most prominent pure-play medicinal cannabis company on the London market. The company operates a pharmaceutical-grade cultivation facility in the Midlands and holds the regulatory permissions needed to supply cannabis-based medicines commercially, alongside a clinical programme focused on chronic pain. For investors, Celadon represents the thesis that UK-grown, pharmaceutical-quality product can displace imports in a prescription market that continues to expand.

Kanabo Group (LSE:KNB) approaches the space from a different angle, combining medical cannabis products with a digital health and telehealth offering that connects patients to clinicians. Its strategy reflects a wider truth about the UK market: access and distribution matter as much as cultivation. Oxford Cannabinoid Technologies (LSE:OCTP), meanwhile, sits firmly at the drug-development end of the spectrum, researching cannabinoid-derived compounds for pain conditions, with the long timelines and binary catalysts that characterise early-stage pharma. Hellenic Dynamics (LSE:HELD) adds a continental dimension, focused on cultivation in Greece with an eye on European demand, particularly the German market following its liberalisation moves.

Is there any shelter in the medicinal story?

Interestingly, the part of the sector closest to healthcare may be the part best insulated from the current macro storm. Prescription demand for cannabis-based medicines in the UK has been growing steadily, driven by private clinics treating chronic pain, anxiety and sleep conditions. That demand does not ebb and flow with the FTSE 100; patients do not stop renewing prescriptions because a ceasefire in the Middle East looks shaky. For companies with genuine revenue attached to that patient base, the operational story can keep improving even while share prices languish.

The challenge is that markets do not always distinguish between operational progress and sentiment. In risk-off phases, correlation rises and everything speculative tends to be marked down together. The companies that emerge strongest from such periods are typically those with the discipline to keep costs tight, the balance sheet to avoid raising money at depressed prices, and the news flow to remind investors why they listed in the first place.

Cannabis stocks in the UK are not a formal index sector but a thematic grouping that cuts across official classifications. Under the industry classification framework used by the London Stock Exchange, medicinal cannabis companies such as Celadon Pharmaceuticals (AIM:CEL) and Oxford Cannabinoid Technologies (LSE:OCTP) generally fall within health care, under pharmaceuticals and biotechnology, while wellness and consumer-facing cannabinoid businesses may be classified under consumer staples or personal goods. Most UK cannabis names trade on AIM or on the standard segment of the Main Market rather than in the premium FTSE indices, reflecting their early-stage profiles. UK rules permit listings only for businesses whose activities are lawful, which in practice means medicinal cannabis, licensed cultivation for medical use, and CBD wellness products rather than recreational operations.

What should investors be watching from here?

The near-term catalysts for the sector are largely company-specific: licensing updates, supply agreements, clinical milestones and progress on patient access. At the macro level, the variables that matter are the same ones pressuring the wider market. If Middle East tension eases and the US inflation picture allows rate expectations to soften, risk appetite could return to small caps generally, and the cannabis cluster would likely be a beneficiary. If the geopolitical situation deteriorates, the sector's reliance on external funding becomes its biggest vulnerability.

For now, London's cannabis companies are doing what small caps always do in storms: keeping their heads down, conserving cash and waiting for the weather to change. The medicinal cannabis story in the UK has never been about a single trading session. It is a slow-burning structural shift in how medicines are regulated, prescribed and supplied, and that shift continues regardless of where the FTSE 100 closes tonight.